Boothbay Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-30,600
Closed -$14.2M 1937
2024
Q3
$14.2M Buy
+30,600
New +$14.7M 0.32% 38
2016
Q3
Sell
-3,800
Closed -$327K 811
2016
Q2
$327K Buy
+3,800
New +$328K 0.13% 225

Other funds holding VRTX

Boothbay Fund Management's VRTX Position: Q2 2026 in Review

Boothbay Fund Management increased its Vertex Pharmaceuticals (VRTX) stake by 368% in Q2 2026, buying an estimated $2.15M and bringing the position to 6,174 shares worth $3.07M. The position accounts for 0.04% of the portfolio, ranked #523.

Boothbay Fund Management first reported a position in VRTX in Q1 2017 and has held it in 17 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Boothbay Fund Management held 6,174 shares of Vertex Pharmaceuticals worth $3.07M as of Q2 2026.
  • Boothbay Fund Management bought 4,854 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.15M.
  • Vertex Pharmaceuticals made up 0.04% of Boothbay Fund Management's portfolio in Q2 2026, its #523 holding.
  • Boothbay Fund Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 17 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.